Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

被引：0
|
作者：
G Chong
D Cunningham
机构：
[1] Royal Marsden Hospital,
[2] G1 Cancer/Lymphoma Unit,undefined
来源：
British Journal of Cancer | 2006年 / 94卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：937 / 937
相关论文
共 50 条
  • [31] Capecitabineand mitomycin C (MMC) is an active regimen for patients with metastatic colorectal carcinoma (MCRC) resistant to 5FU and irinotecan
    Rao, S
    Cunningham, D
    Ross, PJ
    Price, T
    Ward, C
    Norman, AR
    Hill, ME
    BRITISH JOURNAL OF CANCER, 2003, 88 : S56 - S56
  • [32] OUR EXPERIENCE WITH IRINOTECAN AND BOLUS FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Davidov, Deyan
    JOURNAL OF IMAB, 2009, 15 (01): : 49 - 52
  • [33] Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients
    Vrdoljak, E.
    Omrcen, T.
    Boban, M.
    Hrepic, D.
    JOURNAL OF BUON, 2008, 13 (04): : 513 - 518
  • [34] Irinotecan and mitomycin C (MMC) as salvage therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, irinotecan and/or oxaliplatin based chemotherapy.
    Rodriguez, I
    Viudez, A
    Salgado, E
    García-Foncillas, J
    De La Cámara, J
    Espinós, J
    Garrán, C
    Chopitea, A
    Fernández-Hidalgo, O
    Martín-Algarra, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 308S - 308S
  • [35] Capecitabine plus oxaliplatin in metastatic colorectal cancer - In reply
    Porschen, Rainer
    Arkenau, Hendrik-Tobias
    Kubicka, Stefan
    Greil, Richard
    Seufferlein, Thomas
    Freier, Werner
    Kretzschmar, Albrecht
    Graeven, Ullrich
    Grothey, Axel
    Hinke, Axel
    Schmiegel, Wolff
    Schmoll, Hans-Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) : 5045 - 5046
  • [36] Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer
    Hejna, M
    Köstler, WJ
    Raderer, M
    Tomek, S
    Brodowicz, T
    Scheithauer, W
    Wiltschke, C
    Zielinski, CC
    ANTI-CANCER DRUGS, 2000, 11 (08) : 629 - 634
  • [37] Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer
    Meropol, Neal J.
    Gold, Philip J.
    Diasio, Robert B.
    Andria, Michael
    Dhami, Mandeep
    Godfrey, Thomas
    Kovatich, Albert J.
    Lund, Kirk A.
    Mitchell, Edith
    Schwarting, Roland
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) : 4069 - 4077
  • [38] COI regimen (capecitabine, oxaliplatin, irinotecan) as possible neoadjuvant treatment in metastatic colorectal cancer patients
    Buzzoni, R.
    Bajetta, E.
    Di Bartolomeo, M.
    Ferrario, E.
    Gevorgyan, A.
    Dotti, K. F.
    Mancin, M.
    Platania, M.
    Colombo, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI39 - XI39
  • [39] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Adda, B.
    Farida, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
  • [40] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Renouf, Daniel J.
    Welch, Stephen
    Moore, Malcolm J.
    Krzyzanowska, Monika K.
    Knox, Jennifer
    Feld, Ronald
    Liu, Geoffrey
    MacKay, Helen
    Petronis, Jennifer
    Wang, Lisa
    Chen, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1339 - 1344
12345